Icotyde (icotrokinra hydrochloride)

Where it stands

Icotyde (icotrokinra hydrochloride) is authorised in the EU. The European Commission decision was dated 2026-09-18, and the marketing authorisation holder is Janssen-Cilag International. The therapeutic area is psoriasis.

The authorised indication is moderate to severe plaque psoriasis in adults, and in adolescents aged 12 years and older weighing at least 40 kg, who are candidates for systemic therapy. The adolescent population is part of the EU indication from the outset.

The same substance is also approved in the US. The FDA approved Icotyde on 2026-03-17, about six months before the EU decision. The US holder is Janssen Biotech, and the record lists the product as a tablet. The records do not give the US indication wording, so I cannot say whether the US and EU populations match.

Regulatory pathway and designations

The EU followed the standard sequence. The CHMP adopted a positive opinion on 2026-07-23, and the EC decision followed on 2026-09-18, 57 days later. The CHMP opinion is the scientific recommendation. The EC decision converts it into a legally binding marketing authorisation valid across the EU. The records do not say whether the procedure was standard or accelerated, or whether the authorisation is full or conditional.

The only EU designation recorded is additional monitoring. In the US, the records list NDA220149, new molecular entity status and priority review. Priority review is an FDA review-timeline designation and has no direct EU equivalent. The records give no orphan, PRIME or paediatric-plan information for the EU.

The US record describes a new molecular entity and the EU record carries additional monitoring. This fits the usual EU practice of applying the status to products containing a new active substance, but the records do not state the reason for the EU designation.

Safety and pharmacovigilance

Icotyde is subject to additional monitoring in the EU. Products on this list carry a black inverted triangle in the product information, with a short explanatory statement. Healthcare professionals and patients are encouraged to report any suspected adverse reactions. The status does not mean the product is unsafe. It means the regulators want more intensive collection of post-authorisation safety information.

The records contain no clinical safety data, labelled warnings, contraindications, risk management plan content or post-authorisation safety study obligations. I cannot characterise the safety profile or any risk-minimisation measures from this material. Readers should consult the EU summary of product characteristics and the European public assessment report for that detail.

What to watch

The records show no further scheduled regulatory events. Points to follow up from public sources include the published EPAR and product information, including the adolescent dosing and weight-based use. Also worth checking are any post-authorisation commitments tied to the additional monitoring status, and national launch, pricing and reimbursement steps, which the records do not cover.

On the US side, the next step is to compare the FDA label with the EU product information, particularly the age range and the approved population. The records are silent on both, so any comparison needs the primary labelling documents.